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Abstract
Cationic, amphipathic, α-helical host-defense peptides (HDPs) that are naturally 
secreted by certain species of frogs (Anura) possess potent broad-spectrum anti-
microbial activity and show therapeutic potential as alternatives to treat infections 
by multidrug-resistant pathogens. Fourteen amphibian skin peptides and twelve 
analogues of temporin-1DRa were studied for their antimicrobial activities against 
clinically relevant human or animal skin infection-associated pathogens. For com-
parison, antimicrobial potencies of frog skin peptides against a range of probiotic 
lactobacilli were determined. We used the VITEK 2 system to define a profile of 
antibiotic susceptibility for the bacterial panel. The minimal inhibitory concentration 
(MIC) values of the naturally occurring temporin-1DRa, CPF-AM1, alyteserin-1c, 
hymenochirin-2B, and hymenochirin-4B for pathogenic bacteria were threefold to 
ninefold lower than the values for the tested probiotic strains. Similarly, temporin-
1DRa and its [Lys4], [Lys5], and [Aib8] analogues showed fivefold to 6.5-fold greater 
potency against the pathogens. In the case of PGLa-AM1, XT-7, temporin-1DRa and 
its [D-Lys8] and [Aib13] analogues, no apoptosis or necrosis was detected in human 
peripheral blood mononuclear cells at concentrations below or above the MIC. Given 
the differential activity against commensal bacteria and pathogens, some of these 
peptides are promising candidates for further development into therapeutics for topi-
cal treatment of skin infections.
K E Y W O R D S
antimicrobial peptide, biological screening, HDP
   | 1103GAISER Et Al.
1 |  INTRODUCTION
The alarming increase in incidence of multidrug-resistant 
(MDR), pathogenic bacteria together with the decreasing dis-
covery rates for new antibiotics represents a major societal 
problem and threat to human and animal health. This situa-
tion has heightened interest in naturally occurring host-de-
fense peptides (HDPs), including antimicrobial peptides 
(AMPs), as potential novel therapeutics (Afacan, Yeung, 
Pena, & Hancock, 2012; Mangoni, McDermott, & Zasloff, 
2016). A widely studied class of HDPs is cationic amphip-
athic α-helical peptides, many of which are originally iso-
lated from skin secretions of species belonging to the Anura 
order of amphibians (frogs and toads). Amphibians are, for 
a large part of their lifecycle, confined to warm and moist 
environments with high exposure to bacteria and fungi. 
However, frogs and toads possess excellent immunity to de-
fend themselves against invasion by micro-organisms. It is 
currently believed that as part of their innate immune system 
many species, but not all, produce and secrete a wide variety 
of HDPs via specialized glands in the skin (Conlon, 2011a,b; 
Konig, Bininda-Emonds, & Shaw, 2015). Amphibian pep-
tides were among the first HDPs described nearly three de-
cades ago (Giovannini, Poulter, Gibson, & Williams, 1987; 
Zasloff, 1987), and they form a highly diverse group of pep-
tides comprising between 8 and 48 amino acid residues and 
generally a net charge between +2 and +6 at pH 7 (Wang, 
Li, & Wang, 2015). Production of amphibian skin peptides 
seems to be evolutionarily conserved, presumably due to their 
role in preventing infection by pathogenic microbes, although 
T A B L E  1  Bacteria used in this study
Bacterial species Strain Source
Commensal/probiotic Lactobacillus plantarum WCFS1 TIFN




Lactobacillus salivarius FortaFit Ls-33 Danisco
Lactobacillus casei R0215 Rossell
Lactobacillus casei Shirota Yakult
Lactobacillus johnsonii LC-1 Nestle
Lactobacillus reuteri ATCC55730 BioGaia
Lactobacillus acidophilus LA5 Chr Hansen
Pathogenic/opportunistic Streptococcus suis S10 3881 CVI (Vecht et al., 1992)
Staphylococcus aureus DMS 20231 DSMZ
Staphylococcus aureus Sens 8325.4 EMC
Staphylococcus aureus MRSA B33424 EMC
Staphylococcus pseudintermedius E138 KU
Staphylococcus pseudintermedius E139 KU
Staphylococcus pseudintermedius E140 KU
Staphylococcus pseudintermedius S70E2 KU
Staphylococcus pseudintermedius S70E8 KU
Staphylococcus pseudintermedius S70F3 KU
Pseudomonas aeruginosa 26228 KU
Pseudomonas aeruginosa 25467 KU
Pseudomonas aeruginosa Sens1 PA01 EMC
Pseudomonas aeruginosa Sens2 ATCC27853 EMC
Pseudomonas aeruginosa MDR1 B38084 EMC
Pseudomonas aeruginosa MDR2 B31770 EMC
Enterococcus faecium Sens S1 EMC
Enterococcus faecium Sens S2 EMC
Enterococcus faecium VanA R39 EMC
Enterococcus faecium VanB R44 EMC
Acinetobacter baumannii MDR Bangl 027 EMC
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some skin peptides may also have autocrine or chemotactic 
functions (Conlon, 2011a,b; Konig et al., 2015). Previously, 
certain frog skin peptides have been proposed as candidates 
to treat infections on the basis of their potent and broad-range 
antimicrobial activity against pathogenic bacteria, fungi, and 
protozoa (Conlon & Mechkarska, 2014; Yeung, Gellatly, & 
Hancock, 2011).
A disadvantage of many of these candidate HDPs in 
a therapeutic setting is their hemolytic activity and cy-
totoxicity, although this is typically observed at concen-
trations significantly higher than the minimal bactericidal 
concentration (MBC). However, it is possible to selec-
tively reduce the cytotoxicity of HDPs through systematic 
amino acid substitutions to alter physiochemical proper-
ties, while retaining their potency and broad-spectrum 
antimicrobial activity (Conlon, Al-Ghaferi, Abraham, & 
Leprince, 2007; Conlon, Al-Kharrge et  al., 2007). For 
the above-mentioned reasons, HDPs currently show most 
promise as topical treatments for skin and wound infec-
tions rather than for systemic applications to treat invasive 
disease (Conlon & Mechkarska, 2014; Mangoni et  al., 
2016; Ong et al., 2002).
The aim of this study was to test a range of amphibian 
skin peptides and analogues of temporin-1DRa with differ-
ent physicochemical properties in antimicrobial assays. We 
determined their effect on a selection of pathogens including 
opportunistic bacteria isolated from human or animal skin 
infections and MDR strains. We included several probiotic, 
commensal strains in the assays to investigate the spectrum 
of activity and selectivity of the amphibian HDPs. To bench-
mark the efficacy of these skin peptides, we also determined 
susceptibility of the selected bacteria to commonly used an-
tibiotics using an ISO-certified assay platform.
2 |  METHODS AND MATERIALS
2.1 | Bacteria and culture conditions
Table  1 lists the bacterial strains used in this study and 
their source. Nine probiotic Lactobacilli were previously 
isolated from commercially available products (Meijerink 
et  al., 2012); Lactobacillus plantarum WCFS1 is a single 
colony isolated from L. plantarum NCIMB8826, which was 
originally derived from human saliva (Hayward, 1956). 
Lactobacillus casei Shirota (Yakult®) was originally iso-
lated from the human intestine, and Lactobacillus reuteri 
ATCC55730 was originally isolated from human breast milk 
(Casas & Mollstam, 1998). Streptococcus suis S10 (Vecht, 
Wisselink, van Dijk, & Smith, 1992) was obtained from the 
Central Veterinary Institute (CVI, Lelystad); Staphylococcus 
pseudintermedius and Pseudomonas aeruginosa (strains 
26228 and 25467) were isolated from skin infections in 
dogs and were obtained from University of Copenhagen 
(KU). The Enterococcus faecium, Staphylococcus aureus, 
Acinetobacter baumannii, and P. aeruginosa strains MDR1 
and MDR2 were isolated from clinical samples and were 
obtained from the Erasmus University Medical Centre 
Rotterdam (EMC). Lactobacilli were cultured and as-
sayed in de Man, Rogosa and Sharpe (MRS) broth (VWR 
International) at 37°C under anaerobic conditions. All 
other strains were cultured in Müller–Hinton (MH) broth 
(Oxoid Ltd) at 37°C under aerobic conditions.
2.2 | Bacterial antibiotic 
susceptibility testing
The profile of antibiotic susceptibility of a panel of bacterial 
isolates was determined by the microbroth dilution test using 
the ISO-certified VITEK® 2 system (bioMérieux Benelux 
BV; Funke, Monnet, deBernardis, von Graevenitz, & Freney, 
1998; Garcia-Garrote, Cercenado, & Bouza, 2000). The fol-
lowing antibiotic cards were used: AST-P633 (cefoxitin, ben-
zylpenicillin, oxacillin, gentamicin, kanamycin, tobramycin, 
ciprofloxacin, levofloxacin, erythromycin, clindamycin, lin-
ezolid, teicoplanin, vancomycin, tetracycline, fosfomycin, 
fusidic acid, mupirocin, chloramphenicol, rifampicin, and 
trimethoprim/sulfamethoxazole), AST-N199 (piperacillin/
tazobactam, ceftazidime, cefepime, imipenem, meropenem, 
gentamicin, tobramycin, ciprofloxacin, colistin), and AST-
P586 (ampicillin, sulbactam, cefuroxime, cefuroxime axetil, 
imipenem, gentamycin, streptomycin, moxifloxacin, eryth-
romycin, clindamycin, quinupristin/dalfopristin, linezolid, 
teicoplanin, vancomycin, tetracycline, tigecycline, nitro-
furantoin, trimethoprim/sulfamethoxazole). Bacteria were 
inoculated from glycerol stocks on appropriate growth me-
dium agar plates using sterile plastic loops and incubated at 
37°C overnight, after which single colonies were picked for 
analysis.
2.3 | Peptides
The frog skin peptides and the temporin-1DRa analogues 
(Table 2) used in this study were chemically synthesized and 
purified as previously described (Al-Ghaferi et al., 2010; Ali, 
Soto, Knoop, & Conlon, 2001; Conlon et al., 2006; Conlon, 
Al-Ghaferi, et  al. 2007; Conlon, Al-Kharrge et  al., 2007; 
Conlon et al., 2009; Conlon et al., 2010; Mechkarska, Prajeep 
et  al., 2012, Mechkarska, Meetani et  al., 2012; Olson III, 
Soto, Knoop, & Conlon, 2001). The identities of all peptides 
were confirmed by electrospray mass spectrometry, and their 
purity was >98%. Lyophilized peptides were reconstituted 
in 20 μl 0.1% HCl, and stock solutions were made at 1 or 
2.5 mg/ml in sterile PBS and kept at −20°C until use.
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T A B L E  2  The naturally occurring peptides and temporin-1DRa analogues used in this study and their source species






Magainin-AM1 23 aa GIKEFAHSLGKFGKAFVGGILNQ +2 +0.2 Non-helical
PGLa-AM1 22 aa GMASKAGSVLGKVAKVALKAAL.NH2 +4 +0.83 9–22
CPF-AM1 17 aa GLGSVLGKALKIGANLL.NH2 +2 +1.03 5–14
1.1.2. X. laevis × X. muelleri
PGLa-LM1 21 aa GMASKAGSVAGKIAKFALGAL.NH2 +4 +0.805 9–18
1.2. Silurana
1.2.1. Silurana tropicalis
XT-7 (CPF-ST3) 18 aa GLLGPLLKIAAKVGSNLL.NH2 +2 +1.12 5–13
1.3. Hymenochirus
1.3.1. Hymenochirus boettgeri
Hymenochirin-1B 29 aa IKLSPETKDNLKKVLKGAIKGAIAVAKMV.
NH2
+6 +0.169 5–27
Hymenochirin-2B 29 aa LKIPGFVKDTLKKVAKGIFSAVAGAMTPS +4 +0.466 8–16




Alyteserin-1c 23 aa GLKEIFKAGLGSLVKGIAAHVAS.NH2 +3 +0.748 2–8; 10–21




Temporin-1DRa 14 aa HFLGTLVNLAKKIL.NH2 +3 +0.879 5–14
[Lys4]temporin-1DRa HFLKTLVNLAKKIL.NH2 +4 nd 4–14
 [Lys5]temporin-1DRa HFLGKLVNLAKKIL.NH2 +4 nd 4–14
 [D-Lys4]temporin-1DRa HFLkTLVNLAKKIL.NH2 +4 nd nd
 [D-Lys5]temporin-1DRa HFLGkLVNLAKKIL.NH2 +4 nd nd
 [D-Lys8]temporin-1DRa HFLGTLVkLAKKIL.NH2 +4 nd nd
 [Aib8]temporin-1DRa HFLGTLV[Aib]LAKKIL.NH2 +4 nd 5–14
 [Aib9]temporin-1DRa HFLGTLVN[Aib]AKKIL.NH2 +4 nd 5–14
 [Aib10]temporin-1DRa HFLGTLVNL[Aib]KKIL.NH2 +4 nd 5–14
 [Aib13]temporin-1DRa HFLGTLVNLAKK[Aib]L.NH2 +4 nd 5–14
 [Orn7]temporin-1DRa HFLGTL[Orn]NLAKKIL.NH2 +4 nd nd
 [DAB7] temporin-1DRa HFLGTL[DAB]NLAKKIL.NH2 +4 nd nd
 [TML7] temporin-1DRa HFLGTL[TML]NLAKKIL.NH2 +4 nd nd
3.1.2. Rana boylii
Brevinin-1BYa 24 aa FLPILASLAAKFGPKLFCLVTKKC +4 +1.07 4–12
3.2. Hylarana
3.2.1. Hylarana erythraea
B2RP-Era 19 aa GVIKSVLKGVAKTVALGML.NH2 +3 +1.25 13–16 weak
(Continues)
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2.4 | Antimicrobial assays
The minimal inhibitory concentration (MIC) and minimal 
bactericidal concentration (MBC) of the peptides were de-
termined by standard dilution assays in 96-well microtiter 
plates in two independent experiments (Institute CLaS, 
2008). Serial dilutions of peptide in the appropriate growth 
medium (25  μl) were mixed with bacterial suspension 
(75 μl) to obtain an inoculum of 5 × 105 CFU/ml. Bacteria 
were incubated at 37°C for 18–22 hr, after which bacterial 
growth was measured by absorption at 600 nm using a spec-
trophotometer (Spectramax M5; Molecular Devices). The 
MIC was determined as the lowest concentration at which 
no visible growth was observed. MBC was determined as 
the lowest concentration of peptide at which no viable bac-
teria could be detected, following plating of serial dilutions 
of suspensions from the wells on agar plates. Heatmaps 
were generated using the Multiple Experiment Viewer soft-
ware (Saeed et al., 2003), using Euclidean distance with av-
erage linkage for hierarchical clustering of the data.
2.5 | Human peripheral blood mononuclear 
monocyte (PBMC) cytotoxicity assay
Human peripheral blood mononuclear monocytes were iso-
lated as previously described (van Hemert et al., 2010) with 
modifications. Buffy coats from peripheral blood of three 
healthy donors were obtained from the Sanquin Blood Bank, 
Nijmegen, The Netherlands. Isolated PBMCs were washed 
and resuspended in Iscove's Modified Dulbecco's Medium 
(IMDM) + Glutamax (Gibco, Thermo Fischer Scientific) sup-
plemented with 10% heat-inactivated fetal bovine serum (FBS), 
100 U/ml penicillin, and 100 μg/ml streptomycin (Invitrogen) 
at a final concentration of 1 × 106 cells/ml and seeded (100 μl 
per well) in 96-well tissue culture plates. PBMCs were ex-
posed to peptides at final concentrations of 1, 10, and 100 μg/
ml. Exposure to LPS (1 μg/ml) was used as a positive control, 
and cells with only IMDM served as negative control. After 
exposure for 24 hr, cells were incubated with Annexin V-APC 
and propidium iodide (eBiosciences), and using flow cytom-
etry (FACS Canto II, BD Biosciences), the proportions of live 
(unstained), dead (PI only), early-apoptotic (Annexin V only), 
and late-apoptotic (Annexin V + PI) cells were determined 
(BD FACSDiva). Data are presented as mean values ±SD.
3 |  RESULTS
3.1 | Antibiotic resistance of a panel of 
selected probiotic and pathogenic microbes
We used the bioMerieux VITEK®2 system to assay microbial 
resistance to commonly used antibiotics (EUCAST, 2014) for 
which the mode of action and bacterial target is given in Table 
S1. The VITEK®2 system was chosen as it represents a widely 
used and well-standardized ISO-certified platform used in 
hospitals and medical centers to assess antibiotic resistance of 
clinically sampled microbes. As many Lactobacillus species 
did not grow under the VITEK®2 incubation conditions, their 
antibiotic susceptibility profile is not provided. The data for 
antibiotic resistance of each bacterium (Table 3) were used for 
benchmarking against each of the frog antimicrobial peptides. 
In the first row, the number of antibiotics to which a strain was 
resistant is depicted by a color scheme: Brighter red colors 
correspond to increased antibiotic resistance, and brighter 
blue correspond to increased susceptibility to the tested an-
tibiotics (Table 3). These data provide the baseline resistance 
of a selected set of bacteria to antibiotics, classifying certain 
strains as multidrug resistant (MDR). The reference dataset 
of antibiotic resistance was compared to a dataset of the MIC 
and MBC values for frog antimicrobial peptides and synthetic 
analogues tested against the same strains.
3.2 | Potency of frog skin peptides against 
probiotic and pathogenic microbes
Twelve frog skin peptides were tested for their antimicrobial 
activity against a panel of bacteria. Antimicrobial activities 






Pseudin-2 24 aa GLNALKKVFQGIHEAIKLINNHVQ.NH2 +3 −0.008 2–19; 14–19
Notes: PGLa-LM1 was found in a hybrid frog of X. laevis and X. muelleri (1.1.2) (Mechkarska, Meetani et al., 2012). Single amino acid residue substitutions are 
marked in bold font. The net charge is calculated at pH 7.0. The grand average of hydropathy (GRAVY) is defined as the sum of all hydropathy values divided 
by the length of the sequence (Kyte & Doolittle, 1982). AGADIR (Munoz & Serrano, 1994) was used to predict which residues of the peptide are in an α-helical 
confirmation. Aib, α-aminoisobutyric acid; Orn, ornithine; DAB, diaminobutyric acid; TML, trimethyllysine; nd, not determined.
T A B L E  2  (Continued)
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were determined using a standard microbroth dilution assay 
and are presented as MIC (Figure 1b) and minimal bacteri-
cidal concentration (MBC; Table S2). Figure 1b represents 
the MIC values obtained for the naturally occurring frog skin 
peptides as a hierarchically clustered heatmap, with bright 
green colors corresponding to values of <8 μg/ml and bright 
red colors corresponding to values of >256 μg/ml. The heat-
map shows that temporin-1DRa and XT-7 were effective at 
low concentration (<8 μg/ml) while magainin-AM1 and pseu-
din-2 showed no inhibition of any of the strains tested. With 
the exception of magainin-AM1 and pseudin-2, all the native 
frog peptides tested inhibited all strains of Staphylococcus 
pseudintermedius at MIC = 8 μg/ml. The three hymenochirin 
peptides are clustered together based on the observed MIC 
values, showing activity against Gram-positive MDR S. 
pseudintermedius, vancomycin-resistant Enterococcus fae-
cium and the Gram-negative MDR Acinetobacter baumannii. 
The PGLa peptides are also clustered together based on their 
low MIC against all S. pseudintermedius strains. The strains 
of Pseudomonas aeruginosa were relatively insensitive to the 
frog peptides tested, except for the MDR2 isolate. For the 
Gram-positive bacteria (see Table 1), we compared the MIC 
of selected frog peptides against 9 different species of lacto-
bacilli (Figure 1a, green bars) and 13 pathogenic strains (ex-
cluding S. suis; Figure 1a, orange bars) and measured the fold 
difference in MIC value between these two bacterial groups 
(Figure  1a, purple bars). We found that the Gram-positive 
pathogens were 5.5-fold to ninefold more susceptible to inhi-
bition by CPF-AM1, temporin-1DRa, and alyteserin-1c than 
the probiotic lactobacilli.
Temporin-1DRa, a peptide, first isolated from Rana dray-
tonii (Conlon et al., 2006), showed most promise for thera-
peutic activity against a range of Gram-positive pathogens 
including methicillin-resistant strains of S. pseudintermedius 
which are a major cause of recurring skin and wound infec-
tions in dogs (Bannoehr & Guardabassi, 2012). Additionally, 
the MIC values for temporin-1DRa were ~3.5-fold lower for 
pathogens than probiotic species (Figure 1a).
3.3 | Antimicrobial activities of analogues of 
temporin-1DRa
To investigate whether the antimicrobial activity of tem-
porin-1DRa against pathogenic species could be increased by 
appropriate amino acid substitutions, we tested 12 different 
analogues, having single residue modifications to alter pa-
rameters such as cationicity, hydrophobicity, and α-helicity 
(Conlon, Al-Ghaferi, et al., 2007; Conlon, Al-Kharrge et al., 
2007; Table 2). The effect of these amino acid substitutions on 
F I G U R E  1  (a) Minimal inhibitory concentration (MIC) values of a selection of naturally occurring frog skin peptides against nine Gram-
positive lactic acid bacteria (green) and 13 Gram-positive pathogenic bacteria (orange). The fold difference in MIC between the two groups is 
depicted as purple bars on the secondary axis. Average values ± SEM are shown. (b) Heatmap representation of all MIC values of the tested frog 
skin peptides, including for each peptide its net charge at pH 7 and grand average of hydropathy (GRAVY). The gray color indicates MIC was not 
determined [Colour figure can be viewed at wileyonlinelibrary.com]
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the physicochemical properties of α-helical peptides and the 
subsequent effect on cytotoxicity and antimicrobial potency 
has been described previously (Conlon, Al-Ghaferi, et  al., 
2007; Conlon, Al-Kharrge et al., 2007). We observed MIC 
values that ranged from <8 to >64 μg/ml for these temporin-
1Dra analogues, although multiple isolates of the same spe-
cies showed similar sensitivities to a given peptide (Figure 2; 
Table S3). Figure 2A Shows that the analogues had altered 
activity against bacteria, with [Aib8]temporin-1DRa having 
the largest fold-change (6.5) in activity between the grouped 
Gram-positive pathogenic and probiotic bacteria, followed 
by the [Lys4], [Lys5], and [Aib9] analogues. Incorporation of 
α-aminoisobutyric acid (Aib) into a peptide generally pro-
motes the formation of an α- or 310-helix or stabilizes an ex-
isting helical conformation (Karle & Balaram, 1990).
3.4 | Cytotoxic effects of selected frog 
peptides and temporin-1DRa analogues
In order to determine the cytotoxic activities of peptides with 
most potent antimicrobial activity against pathogenic bac-
teria (PGLa-AM1, XT-7, temporin-1DRa and its [D-Lys8] 
and [Aib13] analogues, we exposed human PBMCs to the 
peptides and quantified apoptosis and necrosis using flow 
cytometry. Figure 3 shows that none of the peptides tested 
had a significant effect on the viability of PBMCs during a 
24-hr exposure to final peptide concentrations of 1, 10, and 
1,000 μg/ml.
4 |  DISCUSSION
Many frogs secrete host-defense peptides (HDPs) into the 
outer skin mucosa (Conlon, 2011a,b; Konig et  al., 2015), 
which may have potent and broad-range antimicrobial activ-
ity against bacteria, fungi, and protozoa. Consequently, HDPs 
are interesting candidates for antimicrobial therapeutic appli-
cations (Conlon & Mechkarska, 2014; Yeung et al., 2011). 
The amphipathic peptides we tested limit growth of several 
multidrug-resistant Gram-positive and Gram-negative path-
ogens. We found that the Pseudomonas aeruginosa strains 
were relatively insensitive to the action of the peptides. This 
is possibly due to the secretion of extracellular proteases that 
aid in their resilience toward peptide antimicrobials (Engel, 
Hill, Caballero, Green, & O'Callaghan, 1998).
The MIC and MBC values obtained for PGLa-AM1, 
PGLa-LM1, CPF-AM1, alyteserin-1c, hymenochirin-2B, and 
hymenochirin-4B and the [Aib8], [Lys4], [Lys5], and [Aib9] 
temporin-1DRa analogues showed promising differential activ-
ity against the pathogenic bacteria Staphylococcus pseudinter-
medius, Enterococcus faecium, and Acinetobacter baumannii 
compared to the probiotic strains of lactobacilli (Figures 1, 2). 
The observed differences in antimicrobial activity between 
F I G U R E  2  (a) Minimal inhibitory concentration (MIC) values of temporin-1DRa analogues against 9 Gram-positive lactic acid bacteria 
(green) and 13 Gram-positive pathogenic bacteria (orange). The fold difference in MIC between the two bacterial groups is depicted as purple bars 
on the secondary axis. Average values ± SEM are shown. (b) Heatmap representing the MIC values of temporin-1DRa analogues against the panel 
of tested bacteria. The gray color indicates MIC was not determined [Colour figure can be viewed at wileyonlinelibrary.com]
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tested peptides and analogues may in part be explained by the 
different α-helicity and peptide stability (Conlon, Al-Ghaferi, 
et  al., 2007; Conlon, Al-Kharrge et  al., 2007). In a recent 
study, it was shown that PGLa-AM1 and CPF-AM1 have po-
tent antimicrobial activity against a selection of oral pathogens 
(McLean et al., 2014). We showed that the Gram-positive lactic 
acid bacteria, which are often present in probiotic supplements 
or food products, are not susceptible at peptide concentrations 
that are bactericidal to these oral pathogens (McLean et  al., 
2014). This highlights the potential of these peptides for selec-
tive antimicrobial therapy against such oral pathogenic bacte-
ria. Both the multidrug-resistant and antibiotic-sensitive strains 
of S. pseudintermedius and E. faecium were sensitive to similar 
concentrations of AMPs, suggesting no cross-resistance.
We also tested the potential cytotoxicity of selected pep-
tides against human PBMCs, as it would be important not to 
inhibit the defensive immune response of the host if these 
peptides were used as topical applications to treat infections. 
We found that concentrations of peptides that effectively in-
hibited bacteria did not cause necrosis or apoptosis against 
human PBMCs.
Based on this study, we propose that peptides alytese-
rin-1c, PGLa-AM1, PGLa-LM1, CPF-AM1, temporin-1DRa 
and its [Lys4], [Lys5], [Aib8], and [Aib9] analogues are in-
teresting candidates for further research into potential use 
as novel topical therapeutics for treatment of skin infections 
caused by antibiotic-resistant bacteria. Based on the observed 
MIC values, temporin-1DRa shows great promise to be used 
to treat canine skin infections by S. pseudintermedius, a bac-
terium that causes high morbidity and seriously lower the 
quality of life of affected dogs (Bannoehr & Guardabassi, 
2012). Moreover, the hymenochirin-2B and -4B peptides dis-
played high potency against multidrug-resistant, A. bauman-
nii, pathogens that cause severe wound infections (Guerrero 
et al., 2010) and are an important cause of difficult to treat 
nosocomial infections (Michalopoulos & Falagas, 2010). 
The differential activity of these antimicrobials against sev-
eral pathogenic bacteria but not lactic acid bacteria might 
be advantageous as many commensal species of bacteria in-
cluding lactobacilli are considered beneficial and potentially 
contribute toward colonization resistance against patho-
genic bacteria (Belkaid & Tamoutounour, 2016; Grice et al., 
2009). For example, Lactobacillus rhamnosus GG has been 
shown to effectively interfere with intestinal colonization by 
Enterococcus faecium. Thus, HDPs reported here that have 
up to ninefold higher MIC values for commensal lactobacilli 
than E. faecium might be advantageous in treatment of inten-
sive care patients with intestinal colonization by vancomy-
cin-resistant enterococcus (Jung, Byun, Lee, Moon, & Lee, 
2014; Tytgat et al., 2016).
F I G U R E  3  Human PBMCs obtained from three healthy donors were exposed to 100, 10, or 1 μg/ml of PGLa-AM1, XT-7, temporin-1DRa, 
[D-Lys8]temporin-1DRa, and [Aib13]temporin-1Dra for 24 hr, stained with Annexin V and PI and apoptotic or dead cells quantified by flow 
cytometry. Iscove's Modified Dulbecco's Medium (IMDM) was used as a negative control, and bacterial lipopolysaccharide (LPS) was used as a 
positive control. Proportions of live (blue), early-apoptotic (red), late-apoptotic (green), and dead (purple) cells are displayed. Error bars depict SD 
of live cells between averaged values of all three donors [Colour figure can be viewed at wileyonlinelibrary.com]
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Recently, several biotechnological tools have become avail-
able that open up avenues to develop promising applications 
for AMPs, including the peptides described in this study (de 
Vries, Andrade, Bakuzis, Mandal, & Franco, 2015). Tethering 
and display of AMPs on nanoparticles, fibers or polymers for 
localized and controlled delivery, increased stability and en-
hanced activity are examples of possible therapeutic applica-
tions of AMPs against MDR pathogenic bacteria in the future.
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